Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Conditions
Cushing Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California San Francisco UCSF, San Francisco, California, United States
ABMED Clinical Research Corp, Cape Coral, Florida, United States
Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
Contact: Principal Investigator (Wendy Brickman)National Institute of Child Health and Human Development, Bethesda, Maryland, United States
Texas Valley Clinical Research, Weslaco, Texas, United States
UZ Brussel, Jette, Brussels Capital, Belgium
Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria
Hospital Necker Enfants Malades, Paris, France
Robert Debre Hospital, Paris, France
CHU Bicetre APHP Paris Saclay, Paris, France
Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello, Pisa, PI, Italy
Ospedale Bambino Gesu, Roma, Italy
University Clinical Center Ljubljana, Ljubljana, Slovenia
Alder Hey Childrens NHS Foundation Trust, Liverpool, United Kingdom
The Royal London Childrens Hospital, London, United Kingdom
Study leads
Recordati AG
Study Director
Recordati AG